Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours

A pharmaceutical compositional said pharmaceutical composition comprising:

• a chemotherapeutic agent conjugated to p97 comprising a dosage unit of from about 0.02 to about 2000 mg/kg of p97, substantially all of which p97 is conjugated to said chemotherapeutic agent;
• and
• a pharmaceutically acceptable carrier therefor.

A method for increasing delivery of a chemotherapeutic agent to a neoplasia localized in or around the brain, said method comprising administering a p97-chemotherapeutic agent to an animal having a neoplasia in or around the brain, wherein the amount of chemotherapeutic agent delivered as part of the p97-chemotherapeutic agent to said neoplasia is increased relative to delivery of the chemotherapeutic agent when said chemotherapeutic agent is not conjugated to p97 and administered at an equivalent dose.

A method for targeting a chemotherapeutic agent to a neoplasia localized in or around the brain, said method comprising administering a p97-chemotherapeutic agent to an animal having a neoplasia localized in or around the brain, wherein said patient experiences increased delivery of said chemotherapeutic agent to said neoplasia compared to when the chemotherapeutic agent is not conjugated to p97 and is administered at an equivalent dose.

A method of treating a neoplasia localized in or around the brain comprising administering to a subject in need thereof a pharmaceutically effective amount of a p97-chemotherapeutic agent.

A p97-chemotherapeutic agent conjugate selected from the group consisting of:

• 23

A modified adriamycin molecule selected from the group consisting of:

• 24

A method of detecting or diagnosing a cancer of the brain comprising administering an effective amount of a composition comprising a radioimaging agent conjugated to p97 to an animal in need thereof.